Zika virus (ZIKV), a member of the Flaviviridae family, is transmitted primarily via Aedes species mosquitos, but sexual transmission has also been documented [1] . Individuals infected with ZIKV may be asymptomatic, have mild disease, or present with symptoms similar to those of other arbovirus infections (eg, fever, rash, muscle and joint pain, malaise, and headache) [2] . However, ZIKV infection can be associated with neurological complications including Guillain-Barré syndrome (GBS). Moreover, ZIKV infection during pregnancy can cause congenital brain abnormalities, including microcephaly, in infants born to mothers infected with the virus (referred to as Zika congenital syndrome [ZCS] ) [3] . The ongoing epidemic in Central and South America with spread to other regions, together with the risk to pregnant women and their offspring, underscore the critical need for a safe and effective vaccine to protect against Zika disease. Challenges to Zika vaccine development include limited understanding about the biology of ZIKV, host factors that might impact disease course, and how prior exposure to other flaviviruses may affect the course of disease and the host immune response. However, studies in animal models have shown that several ZIKV vaccine candidates can induce protective immunity [4] . In addition, several vaccine candidates that are based on different platforms (eg, DNA, RNA, live and inactivated vaccines) have advanced to "first-in-human" clinical trials [5] . Thus, it is important to define clinical development strategies to facilitate licensure and access to vaccines to protect from Zika disease.
As with other preventive vaccines, the strategy for clinical development (defined for the purpose of this document as the prelicensure clinical trials conducted to evaluate and establish the safety and effectiveness of the candidate vaccine) and regulatory licensure for a Zika vaccine must be specifically tailored to the particular vaccine candidate. The strategy may be influenced by the specific attributes of the vaccine, available nonclinical and clinical data for the particular vaccine and/or related vaccines, proposed indication, target population, feasibility of conducting a clinical endpoint efficacy study (ie, a clinical study with an endpoint such as prevention of morbidity of mortality), and the prospects for identification of either an immune response that reliably predicts protection against disease or a surrogate endpoint (immune response or other endpoint) that is reasonably likely to predict clinical benefit. The primary goal of ZIKV vaccination will be to prevent infection and protect against the serious sequelae of the virus, particularly ZCS [3] . While generating evidence of efficacy against the serious sequelae of ZIKV in prelicensure trials may not be feasible within a reasonable time frame and will likely require postlicensure studies, it is nonetheless anticipated that, at least initially, the target population for a ZIKV vaccine will be men and nonpregnant women of reproductive age. Although this article is devoted to the clinical development strategy for a Zika vaccine and regulatory pathways to licensure, data demonstrating that the manufacturing process will ensure product consistency and quality and assurance that the facility is compliant with current Good Manufacturing Practices are needed to support product licensure.
CLINICAL DEVELOPMENT OF ZIKA VACCINES
The clinical development strategy for vaccines to prevent emerging infectious diseases such as Zika must take into account the epidemiology of the disease, the infrastructure for conducting clinical trials in affected areas, and the regulatory framework to support licensure. Of note, the regulatory standards for demonstration of safety and effectiveness for emerging infectious diseases are the same as for any other preventive vaccine.
The phases of vaccine clinical development typically progress from phase 1, which comprises the "first-in-human" clinical trials conducted to assess safety and preliminary immunogenicity of the vaccine candidate in human subjects for the first time, to phase 2 exploratory studies to further describe dose relationship to safety and immunogenicity, and then to phase 3 pivotal studies to demonstrate the safety and effectiveness of a vaccine in support of licensure. The epidemiology of the disease is likely to have a major impact on the timing and design of phase 3 studies. Considering the current Zika outbreak and urgent public health need for preventive vaccines, it is conceivable that intervals between all phases of evaluation might be compressed and overlapping, provided that preliminary safety data are reassuring. Adaptive elements can be prespecified in the phase 2 and phase 3 designs to expedite clinical trial decisions based on preliminary results derived from earlier trials and, in some cases, from the same trial. To ensure that studies will meet licensure requirements, including requirements for ethical conduct, close communication is essential between public health authorities, national regulatory authorities, the community, clinical investigators, and the vaccine developers.
Phase 1 Studies
Phase 1 vaccine studies to obtain preliminary safety and immunogenicity data can be uncontrolled or may include a placebo control with randomization to either open-label or blinded treatment assignment. These studies generally would be first conducted in a small number (eg, <100) of healthy adult volunteers previously unexposed and at low risk of Zika disease. However, depending on the outbreak, larger phase 1 clinical studies to increase the early safety and immunogenicity database, as well as study populations similar to the eventual target population(s), may be considered to facilitate timely initiation of phase 2 clinical studies. It is possible that the immune responses induced by a ZIKV vaccine candidate may differ in individuals with prior exposure to flaviviruses compared to flavivirus-naive individuals. Therefore, prevaccination sera should be collected in early-phase trials to assess preexisting antibodies to Zika and other flaviviruses and to evaluate how prior infection with other flaviviruses, such as yellow fever and dengue, or vaccination against these viruses may impact the immune response of a Zika candidate vaccine.
Phase 2 Studies
In the absence of safety concerns from short-term postvaccination follow-up in phase 1 studies, development may proceed to phase 2 studies in parallel with continued collection of final safety data from phase 1 studies. Phase 2 studies typically involve up to several hundred subjects and are frequently randomized and controlled. They provide further information on safety and immunogenicity to support initiation of phase 3 studies and are designed to provide more definitive data on dose, schedule, and, if applicable, route of administration. Phase 2 studies should be conducted in the proposed target population, such as individuals at risk for ZIKV infection.
Phase 3 Studies
The purpose of phase 3 clinical studies is to provide an expanded safety evaluation and a rigorous assessment of vaccine effectiveness that may include direct evaluation of efficacy in protecting against clinical disease. The population for phase 3 clinical trials with Zika vaccine candidates should consist of individuals at high risk for the disease (eg, populations residing in Zika outbreak areas). Ideally, effectiveness is evaluated in randomized, double-blind, well-controlled trials with a parallel control group receiving an inert placebo such as saline injection or a vaccine that provides protection against an unrelated disease. Other study designs for obtaining effectiveness data for Zika vaccine candidates (eg, cluster randomized trials) may be considered with careful attention to the ethics and to potential biases of these alternative methods.
For study designs with a clinical disease endpoint, large sample sizes may be needed, particularly if the incidence rate of the disease in the study population is expected to be low or to decline during the study period. Adequate statistical justification for the size and duration of the trial, contingency plans for changing epidemiology, trial endpoints, and criteria for evaluating endpoints should be prespecified prior to initiation of the study. Critical aspects of clinical disease endpoint efficacy studies, in general, include an appropriate control group, appropriate methods for randomization, a prespecified primary endpoint (eg, Zika disease or ZIKV infection, with laboratory confirmation of ZIKV infection), prespecified important secondary endpoints, prespecified, detailed clinical case definitions for the primary and important secondary endpoints, validated diagnostic assays to support the pivotal efficacy analyses, unbiased case ascertainment methods, and adherence to relevant statistical principles. Measures to reduce potential bias are particularly important for designs other than randomized, blinded trials with a parallel control group. If interim analyses for efficacy are planned, detailed information should be included in the protocol regarding their timing, the type I error allocated to each analysis, and stopping rules for demonstration of clinically meaningful efficacy, futility, or harm.
Phase 3 efficacy studies provide an opportunity to identify an immune correlate of protection (ICP). Derivation of a serological ICP is facilitated by the availability of serum samples from a relatively large number of vaccinated participants who do or do not develop disease. Thus, for all Zika vaccine clinical disease endpoint efficacy trials, pre-and postvaccination serum samples would ideally be collected from all subjects, with postvaccination sampling at regular predefined intervals throughout the study period. If this is not feasible, pre-and postvaccination serum samples should be collected from as many subjects as possible.
Even if it is not possible to identify an ICP from a clinical endpoint efficacy trial, immunogenicity data from phase 2 and phase 3 studies are critical to alternative approaches to demonstrate vaccine effectiveness based on surrogate immune response endpoints reasonably likely to predict protection and/ or challenge/protection studies conducted in animal models as described below. In all of these situations, the immunologic assay should be validated for its intended purpose. It is also important to note that the applicability of an ICP or an immunologic surrogate endpoint depends on vaccine characteristics such as antigen structure, mode of delivery, and antigen processing in the vaccinated subject. Thus, a surrogate endpoint identified for a particular vaccine candidate may not be applicable to other vaccine candidates, unless available data provide reasonable evidence that the specific marker (eg, a certain neutralizing antibody titer) reflects the immunologic mechanism responsible for conferring protection against disease.
Clinical Evaluation of Zika Vaccine Candidates in Pregnant Women
The clinical evaluation of Zika vaccine candidates intended for use in pregnancy follows a similar strategy as those for use in nonpregnant individuals. However, unique considerations apply for these products that are described in detail elsewhere [6] . In brief, the clinical development for a vaccine for use in pregnant women typically starts with phase 1 safety testing in healthy adults, including nonpregnant women of childbearing age. Only the vaccine regimens which yield preliminary promising results with regards to safety and activity in women of childbearing age who are not pregnant should be advanced into early studies of pregnant women. Sufficient data to make this determination may require information from larger phase 2 studies in nonpregnant women. Favorable data from phase 2 studies in nonpregnant individuals would support proceeding to phase 1 studies in pregnant women at low risk for pregnancy complications. Adequate data from phase 1 studies conducted in pregnant women would then support proceeding to phase 2 clinical trials in pregnant women who are at low risk for pregnancy complications. Studies should be designed to assess safety parameters such as local and systemic events in the pregnant mother, as well as pregnancy and perinatal outcomes. Pivotal phase 3 studies should ideally have a double-blinded, randomized design with a control group of pregnant women who receive saline placebo. Efficacy studies with a well-defined primary clinical endpoint (eg, prevention of illness, clinical finding, or outcome) represent the gold standard for supporting licensure. However, as discussed further below, prelicensure studies in pregnant women to evaluate the effect of vaccination on the occurrence of congenital infection may be challenging, and thus alternate approaches to demonstrate vaccine effectiveness may need to be considered and should be discussed and agreed upon between a vaccine manufacturer and the US Food and Drug Administration (FDA).
Human Challenge Studies
Human challenge studies, in which consenting volunteers are exposed to a fully virulent or attenuated pathogen under controlled conditions, have been conducted for other diseases (eg, malaria) to demonstrate "proof of concept" of the vaccine early in clinical development [7] . Furthermore, human challenge studies may also be conducted to demonstrate efficacy of a vaccine. For example, in June 2016, FDA licensed a live, oral cholera vaccine for use in adult travelers to cholera-affected countries based on evidence of effectiveness derived from human challenge studies. Human challenge studies have also been proposed to evaluate the effectiveness of Zika vaccine candidates. In December 2016, the National Institute of Allergy and Infectious Diseases and the Walter Reed Army Institute of Research convened a committee to evaluate the conditions under which ZIKV human challenge trials would be ethically justified. The committee concluded that, under certain conditions, human challenge trials could be ethically justified; however, additional information, including data to address uncertainty about the risk to potential volunteers in a ZIKV human challenge study and risk to third parties (eg, rates of GBS, possible other neurological adverse effects, and duration of persistence of ZIKV in semen with risk of sexual transmission), would be needed to ethically justify such studies [8] .
Access to Investigational Zika Vaccine Candidates
If preliminary clinical data suggest possible effectiveness of a vaccine, there may be interest in making that vaccine more broadly available in non-placebo-controlled settings before it is licensed. For example, if efficacy trials have been completed using pilot lots of vaccine, the manufacturer may not yet have met the requirement for licensure of demonstrating the ability to consistently manufacture the vaccine. Depending on the circumstances, vaccine can be made available prelicensure as part of additional studies conducted under an investigational new drug (IND) application, through the IND expanded access mechanism [9] , or through an Emergency Use Authorization (EUA) [10] . Of note, if safety or effectiveness data still need to be collected to support licensure, the vaccine should be made available by enrolling subjects in clinical trials conducted under IND so as not to compromise the successful clinical development and collection of data required for vaccine licensure. For example, data to support effectiveness can be obtained in immunogenicity studies that compare Zika-related outcomes between subjects with high and low vaccine responses. If there is a public health need to provide access beyond such studies and doing so will not interfere with the conduct of clinical studies needed to develop a Zika vaccine for licensure, FDA's IND expanded access provisions may be the most appropriate access mechanism if the public health need can be met while at the same time complying with its requirements that ensure important human subject protections (eg, informed consent, institutional review board approval). The EUA mechanism may be more appropriate when IND clinical studies and Expanded Access provisions cannot adequately address the public health need.
DEMONSTRATION OF EFFECTIVENESS OF ZIKA VACCINE CANDIDATES

"Traditional Approval" Pathway
Under FDA's "traditional approval" pathway, direct demonstration of vaccine effectiveness is either based on a clinical disease endpoint (ie, prevention of Zika disease) or, alternatively, a scientifically well-established marker of protection. In the case of ZIKV disease, currently there is no scientifically well-established ICP. Although it may be possible to identify an ICP in the context of effectiveness studies, if the traditional approval pathway is currently considered for a Zika vaccine, demonstration of effectiveness would likely be based on either a clinical disease and/or prevention of infection endpoint(s).
The incidence of Zika disease and the infrastructure for conducting clinical trials in affected areas are primary determinants of the design of phase 3 clinical endpoint studies to evaluate vaccine efficacy. Prospective randomized, double-blind trials with a parallel control group and a ZIKV disease endpoint enable the most direct assessment of vaccine efficacy when no licensed efficacious vaccine is available. This design avoids potential bias in the assessment of endpoints and maximizes the chance that a difference in disease incidence observed between the vaccinated and unvaccinated groups is due to a true effect of the vaccine being evaluated. The unit of randomization is usually the individual subject enrolled in the trial, although other units of randomization may be considered.
Rapidly changing and/or declining incidence rates during an outbreak may need to be considered when choosing a study design and study endpoints. In some circumstances, other designs such as cluster randomized trials in which selected geographically distinct communities serve as the randomized unit may be an acceptable trial design to establish vaccine effectiveness. For cluster randomized trials, data should be analyzed using statistical methods appropriate for the study design and study objectives. If statistical inferences will be at the usual individual level rather than the cluster level, sample size calculations and statistical analysis methods will need to appropriately address variability in outcomes among the clusters.
Randomization should be carefully planned to reduce the impact of imbalance in disease risk or incidence rate between different groups of clusters.
Trials conducted outside the United States may be necessary to demonstrate vaccine efficacy if the disease has a low incidence in the United States. FDA regulations permit the acceptance of foreign clinical studies in support of an approval, provided certain conditions are met [11] . Under these regulations, to support an application for marketing approval, studies generally must meet FDA standards for an adequate and well-controlled study. This includes a study that is both well designed to permit a valid comparison with a control to provide a quantitative assessment of effect and that is well conducted, meeting standards for Good Clinical Practice, review and approval by an independent ethics committee, and provision of informed consent to study subjects. These principles are discussed in the FDA guidance for industry, titled "General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases" [12] .
Of note, it may not be possible to evaluate the effect of vaccination on the occurrence of the most clinically concerning aspects of Zika infection/disease (ie, neurological complications including GBS or congenital infection leading to neurological malformations) in prelicensure studies. The incidence of ZCS after infection during the first trimester of pregnancy is estimated at 0.88%-13.2%, and the incidence of GBS is estimated at 0.24 cases per 1000 ZIKV infections [13, 14] . In addition, these outcomes may occur in the absence of symptomatic infection. Thus, evaluating these outcomes in prelicensure clinical trials may not be feasible, and considerations may be given to evaluate these outcomes in the postlicensure setting. Therefore, FDA would consider ZIKV infection or symptomatic disease as the primary endpoint for evaluation of vaccine efficacy in prelicensure clinical trials, provided validated assays are available to reliably detect ZIKV infection in subjects.
Accelerated Approval Pathway
FDA's Accelerated Approval provision applies to products that provide meaningful clinical benefit over existing treatments for serious or life-threatening illnesses. It is designed to expedite development of such products by using an appropriate, more readily measured, surrogate or intermediate clinical endpoint when otherwise a lengthy trial would be needed to measure their direct clinical benefit. Even though Zika disease is primarily mild, and clinical disease may only develop in a minority of those infected with the ZIKV, serious sequelae of the virus, such as ZCS following in utero infection, render these provisions applicable to vaccines to prevent Zika disease. Under the Accelerated Approval provisions, FDA may grant marketing approval for a biological product on the basis of adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity [15] . The applicant must study the biological product further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. These postmarketing studies must be adequate and well-controlled, must be conducted with due diligence, and would usually be under way already at the time of licensure. Of note, under accelerated approval, confirmatory postmarketing studies are required because of uncertainty whether the surrogate endpoint (eg, an antibody titer induced by a Zika vaccine candidate) is predictive of vaccine effectiveness. In contrast, under traditional approval, in situations where vaccine effectiveness is based on a scientifically well-established ICP, no postmarketing studies to confirm clinical benefit are required because the ICP has been demonstrated to predict effectiveness (eg, antibody titers induced by tetanus and diphtheria vaccines).
For a Zika vaccine candidate, approval under the Accelerated Approval provision would be based on adequate and well-controlled clinical trials establishing an effect of the product on a surrogate endpoint (eg, some measure of an immune response) that is reasonably likely to predict clinical benefit. In this regard, the ZIKV belongs to the family of flaviviruses, which are vector-transmitted single-stranded RNA viruses that also include dengue, yellow fever, and Japanese encephalitis viruses. It has been established that neutralizing antibody titers induced by yellow fever vaccines correlate with protection from disease. In addition, determination of effectiveness of Japanese encephalitis vaccines is based on measurement of neutralizing antibodies. For dengue vaccines, neutralizing antibody titers appear to protect against homologous serotypes, although the role of neutralizing antibodies in protection against heterologous serotypes remains controversial. Similar to yellow fever and Japanese encephalitis viruses, only one serotype of ZIKV is known to exist. Based on these considerations, neutralizing antibodies induced by ZIKV vaccines could potentially serve as a surrogate endpoint reasonably likely to predict clinical benefit. Nevertheless, studies to accrue evidence supporting neutralizing antibody as surrogate endpoint and/or to identify an alternative immune marker(s) to serve as surrogate endpoint would be critical toward achieving approval of a Zika vaccine under the accelerated approval provisions.
Evidence for a surrogate endpoint could be derived from clinical studies and/or through a combination of human and animal data. Such evidence may include data on immune responses in individuals vaccinated with Zika vaccine candidates in phase 1 and 2 studies conducted in endemic and nonendemic areas. It would be important to generate data from immunologic assessments of subjects at baseline, that is, prevaccination, and at prespecified intervals following vaccination. Prevaccination titers are important to differentiate between antibody levels that can be achieved in vaccinated individuals who may already have been exposed to ZIKV or other flaviviruses compared with flavivirus-naive individuals. Postvaccination data will be important to compare vaccine-induced antibody responses in subjects protected from disease with those in subjects who contract Zika. A correlation between levels of antibody and clinical protection from disease could be useful in identifying a surrogate endpoint reasonably likely to predict protection, even if the data do not establish a definitive protective level. In addition to evaluating antibody responses in general, assessment of functional antibodies (eg, neutralizing antibody titers) will be important. Supportive data may also include immune response evaluations to ZIKV derived from natural-history studies of individuals who are known to have had or who are at risk of developing ZIKV disease. Serologic tests must be able to differentiate between antibody responses to Zika and antibody responses to related flaviviruses, including dengue and possibly yellow fever. At present, this remains a challenge and an area of intense investigation by researchers and diagnostic developers. Also, because the primacy of the humoral response in protection from Zika disease is not established, it would be prudent for developers to document relevant T-cell responses, both as a result of naturally acquired disease and in those who receive candidate novel Zika vaccines.
Several animal models are currently in development to assess ZIKV disease and immune responses induced by either the ZIKV or ZIKV vaccine candidate(s). These include mouse, hamster, and rhesus macaque models. From the FDA perspective, there is no requirement for a particular animal model as long as data are available to demonstrate the relevance to human Zika disease of the model that is used to identify a surrogate endpoint reasonably likely to predict clinical benefit. Antibody titers achieved in vaccinated animal models (eg, nonhuman primates) that correlate with protection from ZIKV challenge could help to determine a surrogate endpoint (eg, antibody level). In addition, adoptive transfer studies demonstrating that antibodies induced in humans vaccinated with a particular ZIKV vaccine candidate can protect animal models from ZIKV disease would be helpful in identifying a surrogate endpoint and in determining the magnitude of the response necessary to confer the protective effect. The identification of such immune marker requires the availability of validated assays to reliably measure these antibodies.
"Animal Rule" Approval
Approval under the "animal rule" may be considered for products for certain serious or life-threatening conditions when definitive human efficacy studies are not ethical or feasible [16] . Notably, this approval pathway does not apply when other FDA efficacy standards (eg, the accelerated approval based on surrogate markers or clinical endpoints other than survival or irreversible mortality) can be used, and thus, the animal rule may not be applicable to Zika vaccines at present. This regulation provides for FDA to license vaccines based on adequate and well-controlled animal studies when the results of those animal studies establish that the vaccine is reasonably likely to produce clinical benefit in humans, provided that safety in humans has been established. For example, for "animal rule" approval of a Zika vaccine, evidence for effectiveness may be derived from challenge/protection studies in an appropriate nonhuman primate model(s). The animal study endpoint must be clearly related to the desired benefit in humans, generally the "enhancement of survival or prevention of major morbidity. " Other regulatory requirements under this provision include meeting certain criteria for the animal model(s) and the accrual of data or information, in animals and humans, to allow selection of an effective dose in humans. Postmarketing studies to verify the product's clinical benefit and to further assess safety must be conducted at a time when such studies are feasible and ethical. Further information regarding the animal rule can be found in the FDA Guidance for Industry document titled "Product Development Under the Animal Rule" [17] .
As discussed above, studies in animal models can help to determine a surrogate endpoint reasonably likely to predict benefit to facilitate an approval under the Accelerated Approval provision; however, an approval under the animal rule requires that animal studies satisfy additional criteria as described in the FDA Guidance for Industry [17] .
When immune markers identified in animal challenge studies are used to define immune response endpoints for effectiveness evaluation or to infer clinical benefit under either Accelerated Approval or the animal rule, these studies should be conducted using an appropriate dose range and an adequate number of animals such that the relationship between immune response and protection and the protective threshold can be estimated with satisfactory precision.
DURATION OF PROTECTIVE IMMUNE RESPONSE AND NEED FOR BOOSTER VACCINATIONS
Clinical development and licensure of Zika vaccines will need to consider the durability of vaccine-induced protection and the potential need for booster doses. Evaluation of these questions could be facilitated by the identification of an ICP. It may be necessary after completion of efficacy trials to follow subjects into the postlicensure period or to conduct postmarketing surveillance studies to collect data on long-term protection and the need for, and timing of, booster immunization. In situations where data from animal studies support vaccine effectiveness, consideration should be given to how the interval between completion of the vaccination regimen and challenge affects the level of protection and corresponding prechallenge measures of immunity.
DEMONSTRATION OF SAFETY OF ZIKA VACCINE CANDIDATES
Safety of a Zika vaccine candidate is evaluated in all phases of clinical development, though most of the safety data will likely be collected as part of studies designed to demonstrate the effectiveness of the product. Separate safety studies may need to be conducted to further evaluate safety signals observed in earlier studies. The size of the safety data base required to support licensure may depend on several parameters including the characteristics of the particular vaccine candidate, its intended use, the target population, and severity of disease to be prevented. Specific safety monitoring methods should be tailored to the specific study population (eg, children, adults, pregnant women, persons in areas where Zika is endemic) and with consideration given to adverse events known to be associated with a particular vaccine candidate or platform. It is important for the study protocol to specify methods for monitoring and documenting adverse events. These methods may include the use of subject diaries and case report forms, procedures to inquire about adverse events at study visits, use of severity grading scales, and specification of criteria for adverse event categories (eg, serious adverse events [SAEs] and adverse events of special interest [AESI]). It is also important to establish rules for discontinuing subsequent doses for individual study participants who experience certain SAEs, as well as rules for halting study enrollment and vaccinations overall if concerning safety signals arise. In particular, for trials evaluating major morbidity as a primary endpoint, trials for which there is heightened concern regarding safety of trial participants, and trials for which external changes (eg, disease epidemiology) are expected to potentially prompt interest in trial modifications, consideration should be given to the establishment of an independent data monitoring committee [18] .
In early-phase clinical studies (and at later phases if warranted), pre-and postvaccination assessment of safety laboratory parameters, including hematologic and clinical chemistry evaluations, may be appropriate depending on the vaccine. If such parameters are monitored, grading scales appropriate for the study population should be utilized. In phase 1 and 2 studies, all participants should be monitored for prespecified, solicited local and systemic adverse reactions at specified time points, and for a specified period following vaccination. In phase 3 studies, it may be acceptable to monitor actively only a subset of participants (eg, several hundred per group) for common, nonserious local and systemic adverse reactions and to monitor all participants for SAEs and AESIs. Assessment of possible causal associations between vaccination and adverse events can be facilitated by comparison of adverse event rates between vaccine and placebo control groups, or if such comparisons are not possible by knowledge of background rates of events in the relevant general population.
Safe and effective vaccines are an important tool to prevent and control ZIKV disease and its serious sequelae. The clinical development strategy of these products will require regulatory flexibility and adjustment to approaches for demonstrating effectiveness. A key feature common to all approval provisions is that the established regulatory standards for the demonstration of safety and effectiveness are maintained. If licensure using the traditional approval pathway is no longer feasible because of changing disease epidemiology, accelerated and animal rule approval could provide an alternative science-based approach to the demonstration of vaccine effectiveness to protect against ZIKV disease. By fostering a high level of communication with its stakeholders, FDA will continue to employ its science-based regulatory approaches to expedite Zika vaccine licensure and thus, facilitate the availability of safe and effective Zika vaccines.
